MOG79–90 Peptide in Complex with Recombinant MHC Class II Molecules Ameliorates Experimental Autoimmune Encephalomyelitis

ABSTRACT

The recent advancement in the field of biomedical technologies has opened up new possibilities in the treatment of autoimmune disorders such as multiple sclerosis (MS). Here, we report the production of soluble complexes between the myelin oligodendrocytic glycoprotein (MOG) 79–90 peptide and a genetically engineered murine MHC class II molecule A^q. Using mouse model of MS, we demonstrate that the generated complexes are functional and able to ameliorate the clinical signs and reduce the incidence of experimental autoimmune encephalomyelitis (EAE). Our findings offer a new possibility for the treatment of chronically active autoimmune inflammation such as multiple sclerosis.

Keywords:

• multiple sclerosis
• experimental autoimmune encephalomyelitis
• vaccination
• MHC II/peptide complex
• myelin oligodendrocytic glycoprotein
• T cells